Aegis Capital has issued a ‘Buy’ rating and price target of $27 on Nektar Therapeutics (NASDAQ: NKTR), stating that the company’s NKTR-214 has wide applicability and the ability to be combined effectively with multiple modalities such as checkpoint inhibitors, cell therapies, small molecules, or vaccines. The company has many upcoming catalysts, including an expansion of the Bristol-Myers Squibb Opdivo collaboration expected in the third quarter of 2017 and a collaboration with Roche Holding’s Tecentriq trial that is expected to initiate by mid-2017.
For more information, visit www.nektar.com
About Nektar
Nektar Therapeutics is a research-based biopharmaceutical company that discovers and develops innovative medicines to address the unmet medical needs of patients. The company’s R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. Nektar leverages its proprietary and proven chemistry platform in the discovery and design of new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.
About NetworkNewsBreaks
NetworkNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
